利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1511 条记录 (耗时 0.02 秒)

    Genes Associated with Leishmania Parasite Virulence
    2.
    发明申请
    Genes Associated with Leishmania Parasite Virulence 失效
    与利什曼原虫寄生虫毒力相关的基因

    公开(公告)号：US20080199496A1

    公开(公告)日：2008-08-21

    申请号：US12056764

    申请日：2008-03-27

    申请人： Yosser Ben Achour ,  Mehdi Chenik ,  Hechmi Louzir ,  Koussay Dellagi

    发明人： Yosser Ben Achour ,  Mehdi Chenik ,  Hechmi Louzir ,  Koussay Dellagi

    IPC分类号： C12N9/90 ,  C12N15/52 ,  C12N1/21 ,  C07H21/00 ,  A61K38/52 ,  A61K31/7088 ,  A61K35/74 ,  A61K35/68 ,  C07K14/44 ,  A61K38/12 ,  G01N33/53 ,  C07K16/00

    CPC分类号： C12Y503/04001 ,  C07H21/04 ,  C07K2319/00 ,  C12N9/90 ,  Y02A50/41

    摘要： The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerase (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.

    摘要翻译： 本发明涉及打击利什曼病的领域。 所述发明的结果是从利什曼原虫的野生分离物中分离出称为LmPDI的蛋白质编码基因，其具有与蛋白质的潜在活性位点的序列（Cys-Gly-His-Cys）相同的两个区域 二硫化异构酶（PDI）。 LmPDI蛋白主要在寄生虫的最强毒株中表达。 所述蛋白质形成用于开发抗利什曼病药物的新型治疗靶标和可用于免疫原性和可能接种疫苗的制剂的组合物的新颖元件，其旨在保护人或动物宿主免受利什曼原虫（Leishmania）的侵害。

    Protein homologue of human angiogenin
    4.
    发明授权
    Protein homologue of human angiogenin 失效
    人血管生成素的蛋白质同源性

    公开(公告)号：US5171845A

    公开(公告)日：1992-12-15

    申请号：US392977

    申请日：1989-08-21

    申请人： Genevieve Spik ,  Andre Tarjar ,  Jean Montreuil

    发明人： Genevieve Spik ,  Andre Tarjar ,  Jean Montreuil

    IPC分类号： A61K38/00 ,  C07K14/515 ,  G01N33/574

    CPC分类号： G01N33/574 ,  C07K14/515 ,  A61K38/00 ,  G01N2333/515 ,  Y10S436/817 ,  Y10S530/806 ,  Y10S530/832

    摘要： The invention concerns a new protein of approximately 17 KD, with angiogenic activity, a process for isolating it from mammalian milk, therapeutic compositions containing it, a process for detecting and/or determining the content of mammalian angiogenins, their homologues and their fragments. Said protein, of bovine origin, has a sequence of 125 aminoacids, 81 of which are common to human angiogenin, and a molecular weight of approximately 17 KD, and is extracted from mammalian milk. Application to the detection of mammalian angiogenin.

    摘要翻译： PCT No.PCT / FR88 / 00566 Sec。 371日期1989年8月21日 102（e）日期1989年8月21日PCT提交1988年11月18日PCT公布。 出版物WO89 / 04837 日本1989年6月1日。本发明涉及约17KD的新型蛋白质，具有血管生成活性，从哺乳动物乳分离其的方法，含有它的治疗组合物，检测和/或确定哺乳动物血管生成素含量的方法， 它们的同源物及其片段。 牛来源的所述蛋白具有125个氨基酸的序列，其中81个是人血管生成素共有的，分子量约为17KD，并且从哺乳动物乳中提取。 应用于哺乳动物血管生成素的检测。

    Novel HCV core+1 protein, methods for diagnosis of HCV infections, prophylaxis, and for screening of anti-HCV agents
    5.
    发明申请
    Novel HCV core+1 protein, methods for diagnosis of HCV infections, prophylaxis, and for screening of anti-HCV agents 审中-公开
    新型HCV核心+ 1蛋白，诊断HCV感染的方法，预防和筛选抗HCV药物

    公开(公告)号：US20110287406A1

    公开(公告)日：2011-11-24

    申请号：US12926387

    申请日：2010-11-15

    申请人： Penelope Mavromara ,  Niki Vassilaki

    发明人： Penelope Mavromara ,  Niki Vassilaki

    IPC分类号： C12Q1/70 ,  C12N5/10 ,  C07H21/04 ,  C07K7/08 ,  C07K14/18 ,  C07K16/10 ,  G01N33/53 ,  C12N15/63

    CPC分类号： C07K5/1013 ,  C07K14/005 ,  C07K16/40 ,  C12N2770/24222 ,  G01N33/576 ,  Y10S436/82

    摘要： The present invention relates to a novel form of core+1 protein of Hepatitis C virus (HCV), designated shorter form core+1 protein. The shorter form core+1 protein of Hepatitis C virus is the product of translation of a coding sequence consisting of all or part of a nucleotide sequence extending from nucleotide 598 to nucleotide 920 within the core+1 ORF of HCV represented on FIG. 3B. The invention also provides methods for detecting infection by Hepatitis C virus in biological samples, methods of screening compounds which interact with viral propagation in HCV infected cells or screening of compounds impaction on the expression of shorter form core+1 protein and uses of these compounds for the preparation of compositions useful for their anti-viral activities.

    摘要翻译： 本发明涉及丙型肝炎病毒（HCV）的核心+ 1蛋白的新型，称为短核心+ 1蛋白。 丙型肝炎病毒的较短形式的核心+ 1蛋白质是由在图1中表示的HCV的核心+ 1 ORF内核苷酸598至核苷酸920的全部或部分核苷酸序列的全部或部分翻译的编码序列的产物。 3B。 本发明还提供用于检测生物样品中丙型肝炎病毒感染的方法，筛选与HCV感染细胞中的病毒繁殖相互作用的化合物或筛选化合物对较短核心+1蛋白表达的影响的方法以及这些化合物的用途 制备可用于其抗病毒活性的组合物。

    HCV core+1 protein, methods for diagnosis of HCV infections, prophylaxis, and for screening of anti-HCV agents
    6.
    发明授权
    HCV core+1 protein, methods for diagnosis of HCV infections, prophylaxis, and for screening of anti-HCV agents 失效
    HCV核心+ 1蛋白，诊断HCV感染的方法，预防和筛选抗HCV药物

    公开(公告)号：US07838002B2

    公开(公告)日：2010-11-23

    申请号：US11322374

    申请日：2006-01-03

    申请人： Penelope Mavromara ,  Niki Vassilaki

    发明人： Penelope Mavromara ,  Niki Vassilaki

    IPC分类号： A61K39/00 ,  G01N33/53

    CPC分类号： C07K5/1013 ,  C07K14/005 ,  C07K16/40 ,  C12N2770/24222 ,  G01N33/576 ,  Y10S436/82

    摘要： The present invention relates to a novel form of core+1 protein of Hepatitis C virus (HCV), designated shorter form core+1 protein. The shorter form core+1 protein of Hepatitis C virus is the product of translation of a coding sequence consisting of all or part of a nucleotide sequence extending from nucleotide 598 to nucleotide 920 within the core+1 ORF of HCV represented on FIG. 3B. The invention also provides methods for detecting infection by Hepatitis C virus in biological samples, methods of screening compounds which interact with viral propagation in HCV infected cells or screening of compounds impaction on the expression of shorter form core+1 protein and uses of these compounds for the preparation of compositions useful for their anti-viral activities.

    摘要翻译： 本发明涉及丙型肝炎病毒（HCV）的核心+ 1蛋白的新型，称为短核心+ 1蛋白。 丙型肝炎病毒的较短形式的核心+ 1蛋白质是由在图1中表示的HCV的核心+ 1 ORF内核苷酸598至核苷酸920的全部或部分核苷酸序列的全部或部分翻译的编码序列的产物。 3B。 本发明还提供用于检测生物样品中丙型肝炎病毒感染的方法，筛选与HCV感染细胞中的病毒繁殖相互作用的化合物或筛选化合物对较短核心+1蛋白表达的影响的方法以及这些化合物的用途 制备可用于其抗病毒活性的组合物。

    Gene associated with leishmania parasite virulence
    7.
    发明授权
    Gene associated with leishmania parasite virulence 失效
    与利什曼原虫寄生虫毒力相关的基因

    公开(公告)号：US07700121B2

    公开(公告)日：2010-04-20

    申请号：US10733232

    申请日：2003-12-12

    申请人： Yosser Ben Achour ,  Mehdi Chenik ,  Hechmi Louzir ,  Koussay Dellagi

    发明人： Yosser Ben Achour ,  Mehdi Chenik ,  Hechmi Louzir ,  Koussay Dellagi

    IPC分类号： A61K39/00 ,  A61K39/39 ,  A61K39/002 ,  A61K39/02 ,  A61K45/00

    CPC分类号： C12Y503/04001 ,  C07H21/04 ,  C07K2319/00 ,  C12N9/90 ,  Y02A50/41

    摘要： The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has two regions that are identical to the sequence (Cys-Gly-His-Cys) of the potential active site of the protein disulphide isomerases (PDI). The LmPDI protein is predominantly expressed in the most virulent isolates of the parasite. Said protein forms a novel therapeutic target for developing anti-leishmaniasis medicaments and a novel element that can be used in the composition of immunogenic, and possibly vaccinating, preparations which are intended to protect a human or animal host against Leishmania.

    摘要翻译： 本发明涉及打击利什曼病的领域。 所述发明的结果是从利什曼原虫的野生分离物中分离出称为LmPDI的蛋白质编码基因，其具有与蛋白质的潜在活性位点的序列（Cys-Gly-His-Cys）相同的两个区域 二硫键异构酶（PDI）。 LmPDI蛋白主要在寄生虫的最强毒株中表达。 所述蛋白质形成用于开发抗利什曼病药物的新型治疗靶标和可用于免疫原性和可能接种疫苗的制剂的组合物的新颖元件，其旨在保护人或动物宿主免受利什曼原虫（Leishmania）的侵害。